Navigation Links
IGI Laboratories Announces Second Quarter 2014 Results

BUENA, N.J., July 24, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic drug development and manufacturing company, announced its financial results for the second quarter ended June 30, 2014.

Second Quarter 2014 Highlights

  • Total revenues of $6.5 million in the second quarter of 2014, an increase of 70% over the same quarter in 2013
  • Total revenues of $13.3 million for the six months ended June 30, 2014, an increase of 78% over the same period in 2013
  • Total revenues generated from the sale of IGI label generic topical pharmaceutical products for the three and six months ended June 30, 2014 were $3.4 million, and $6.3 million, respectively, increases of 146% and 127% over the same periods in 2013, respectively
  • Gross margin increased to 43% for the six months ended June 30, 2014 from 30% in the same period of 2013
  • IGI filed five Abbreviated Drug Applications, or ANDAs, with the U.S. Food and Drug Administration (FDA) in the second quarter of 2014
  • IGI filed an additional ANDA, under a joint development agreement with Impax Laboratories, Inc. in June 2014  
  • IGI received its tentative approval from the FDA for an ANDA for diclofenac sodium 1.5% topical solution, and executed an agreement to enable the company to launch the product in March 2015 after final FDA approval
  • Net loss was $0.3 million in the second quarter of 2014, compared to a net loss of $0.4 million in the same period in 2013
  • Net loss was $0.2 million and $0.7 million for the six months ended June 30, 2014 and 2013, respectively
  • Net loss for the six months ended June 30, 2014 was impacted by the Company's decision to increase research and development costs to $3.4 million, an increase of 132% over the same period in 2013
  • On June 27, 2014, IGI announced the pricing of their underwritten public offering of 4,650,000 shares of its common stock at a price to the public of $5.00 per share.  Subsequently on July 2, 2014, IGI, after giving effect to the exercise of the over-allotment option, sold an aggregate of 5,347,500 shares of common stock in the offering at a public offering price of $5.00 per share.  The net proceeds of the offering were approximately $25.2 million
  • On June 30, 2014 IGI was added to the Russell 3000 Index
  • IGI's President and Chief Executive Officer, Jason Grenfell-Gardner, stated, "The extensive list of accomplishments by the IGI team in the second quarter represents our continued focus on executing our business plan.  We filed six ANDAs in the first few weeks of June, including one under a joint development agreement with Impax Laboratories, Inc.  We received tentative approval of our ANDA for diclofenac sodium 1.5% topical solution in May, and we should be ready to launch the product in March 2015, after final FDA approval.  As of today, we have seventeen ANDAs pending at the FDA, with an addressable market of over $465 million, and four additional ANDAs which we have filed with three of our pharmaceutical partners under joint development agreements.  On the financial front, we increased total revenue 70% over the same quarter last year, and improved margins to end the second quarter of 2014 with a gross margin of 45%, compared to 30% one year ago.  We continue to expect to file at least ten ANDAs in 2014, and we have accelerated our R&D efforts in order to meet our commitments."  Mr. Grenfell-Gardner continued, "We continue to expect revenue to increase between 40% and 45% over 2013.  We are committed to profitability for the year ended December 31, 2014, even though we plan to at least double our spending in research and development in 2014 over 2013."The Company will hold a conference call at 4:15 pm ET on Thursday, July 24, 2014 to discuss the 2nd quarter 2014 results.

    The Company invites you to listen to the call by dialing 1-877-870-4263. International participants should call 1-412-317-0790. Canadian participants should call 1-855-669-9657.  Participants should ask to be joined into the IGI Laboratories, Inc. call.

    This call is being webcast by MultiVu (a PR Newswire Company) and can be accessed in the Investor Relations Section of IGI's website at

     IGI LABORATORIES, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except shares and per share information)(Unaudited)Three months ended June 30,Six months ended June 30,2014201320142013Revenues:Product sales, net

    Research and development income

    437109750268Licensing, royalty and other revenue

    2556662Total revenues

    6,4833,82013,3367,504Costs and Expenses:Cost of sales 

    Selling, general and administrative expenses

    1,1567062,4381,386Product development and research expenses

    2,0288053,3931,463Total costs and expenses

    6,7644,18413,3988,097Operating loss

    (281)(364)(62)(593)Interest expense and other, net

    (64)(39)(116)(67)Net loss 

    Basic loss per share

    ($0.01)($0.01)$0.00($0.02)Weighted average shares of common stock outstanding:  Basic and diluted 

    47,107,09443,206,01646,967,68843,070,335IGI LABORATORIES, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFor the six months ended June 30, 2014 and 2013(in thousands)(Unaudited)20142013Cash flows from operating activities:Net loss $
    Non-cash expenses944389Changes in operating assets and liabilities(1,236)(680)Net cash used in operating activities(470)(951)Net cash used in investing activities (312)(1,575)Net cash provided by financing activities4431,303Net decrease in cash and cash equivalents(339)(1,223)Cash and cash equivalents at beginning of period2,1012,536Cash and cash equivalents at end of period$
    IGI LABORATORIES, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share and per share information)(Unaudited)June 30, 2014December 31, 2013*ASSETSCurrent assets:Cash and cash equivalents$
    Accounts receivable, net5,2514,947Inventories2,7232,869Prepaid expenses and other receivables814641Total current assets10,55010,558Property, plant and equipment, net2,7502,623Product acquisition costs, net1,7061,766Restricted cash, long term5454License fee, net150200Debt issuance costs, net5369Other355157Total assets$
    LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:Accounts payable $
    Accrued expenses2,2342,915Deferred income, current135768Capital lease obligation, current1115Total current liabilities4,6265,221Note payable, bank3,0003,000Other long term liabilities815Total liabilities7,6348,236Commitments and contingenciesStockholders' equity:Common stock, $0.01 par value, 60,000,000 shares authorized; 47,129,621 and 46,748,575 shares issued and outstanding as of June 30, 2014 and December 31, 2013, respectively491487Additional paid-in capital52,50851,541Accumulated deficit(45,015)(44,837)Total stockholders' equity7,9847,191Total liabilities and stockholders' equity$
    *Derived from the audited December 31, 2013 financial statementsAbout IGI Laboratories, Inc.IGI Laboratories is a specialty generic drug development and manufacturing company. Our mission is to be a leading player in the specialty generic prescription drug market.

    IGI Laboratories, Inc. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "believe", "target", "estimated," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Actual results may differ materially from these expectations. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    Logo -


    SOURCE IGI Laboratories, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call
    2. Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare
    3. IGI Laboratories To Hold Conference Call For 2nd Quarter 2014 Results
    4. Columbia Laboratories Expands its Intellectual Property Portfolio Following Receipt of U.S. Patent
    5. IDEXX Laboratories to Release 2014 Second Quarter Financial Results
    6. Millennium Laboratories Announces Strategic Acquisition of RxAnte
    7. Sequenom Laboratories Announces Second National Coverage Agreement For Prenatal Diagnostic Testing Services
    8. Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704
    9. IGI Laboratories, Inc. Completes Its Sixth ANDA Filing For 2013 Under Joint Drug Development And Commercialization Agreement
    10. Temptime Acquires William Laboratories to Expand into Blood Temperature Monitoring Solutions
    11. Avista Capital Partners Announces a Majority Investment in Vertical Pharmaceuticals and Trigen Laboratories
    Post Your Comments:
    (Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
    (Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
    (Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
    Breaking Medicine Technology:
    (Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
    (Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
    (Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
    (Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
    (Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
    Breaking Medicine News(10 mins):